Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_001001890.1 | Alternative | 7288 nt | 1579–2940 |
| NM_001001890.3 | Alternative | 7283 nt | 1588–2949 |
| NM_001001890.2 | Alternative | 7274 nt | 1579–2940 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenThis sequence change creates a premature translational stop signal (p.Ala134Glnfs*2) in the RUNX1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RUNX1 are known to be pathogenic (PMID: 18723428, 24100448). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with RUNX1-related conditions. For these reasons, this variant has been classified as Pathogenic.
"This variant has been reported in ClinVar as Pathogenic (1 clinical laboratories) and as Pathogenic by ClinGen Myeloid Malignancy Variant Curation Expert Panel expert panel."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: RUNX1A107Qfs*2RUNX1A107Qfs*2SomaticNCBI Gene:861|Show additional gene information Variant OverviewRUNX1, a transcription factor involved in hematopoietic differentiation, is altered by mutation or chromosomal rearrangement in various hematologic malignancies.The RUNX1 A107Qfs*2 is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.Hide mutation effect description The mutation effect description for truncating mutations in RUNX1 is: Truncating mutations in RUNX1 are most commonly caused by chromosomal translocations that result in a truncation and fusion of RUNX1 to heterologous proteins, inhibiting its function, and predisposing to certain types of leukemia, lymphomas, and myelodysplastic syndromes (PMID: 15386419, 17394134, 15864279). JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.01 | 53 bp |
| Donor Loss (DL) | 0.03 | -80 bp |
| Acceptor Gain (AG) | 0.0 | 40 bp |
| Donor Gain (DG) | 0.0 | -203 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PVS1 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PS3 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PP5 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)